GlassScriptPhysician profile
Anish A Shah
NPI 1376718767
$22,902.41
in general payments reported to CMS, 2019-2025
7 companies · $43.73 in 2025
The $43.73 reported for 2025 was less than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $31.68 · 2021: $104 · 2022: $495 · 2023: $12K · 2024: $10K · 2025: $43.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $2,078 · Food and Beverage: $881 · Education: $11.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,061.00 |
| Travel and Lodging | $2,078.43 |
| Food and Beverage | $881.49 |
| Education | $11.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $22,193.09 | 2019-2024 | Menopur |
| Emd Serono, INC. | $442.27 | 2019-2023 | |
| Bard Peripheral Vascular, INC. | $132.01 | 2021-2025 | Pristine |
| Cardiovascular Systems INC. | $97.22 | 2022 | |
| Misonix INC | $14.80 | 2020 | |
| Avion Pharmaceuticals | $11.57 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anish Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.